Mary Haak-Frendscho, Ph.D. has been appointed president and chief scientific officer, Takeda San Francisco, Inc. Dr. Haak-Frendscho will be responsible for leading all activities at the company, including overall research and preclinical development, process development studies and operations for antibody therapeutics. Takeda San Francisco, established in November 2007, is a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. of Osaka, Japan.      
   
"Dr. Haak-Frendscho's strong leadership skills and biotechnology experience will greatly contribute to the success of Takeda San Francisco," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda. "Takeda San Francisco will play an increasingly critical role in the expansion of Takeda's R&D capabilities as we look to promote the development of antibody therapeutics, and I am confident that Dr. Haak-Frendscho will help us realize our goals in the antibody field."
   
Dr. Haak-Frendscho has more than 17 years of pharmaceutical and biotechnology experience having held positions at Genentech, Abgenix and most recently, at XOMA, where she served as chief science officer and vice president, preclinical R&D.

News from our sister sites